Skip to Content

Selzentry Approval History

  • FDA approved: Yes (First approved August 6th, 2007)
  • Brand name: Selzentry
  • Generic name: maraviroc
  • Dosage form: Tablets
  • Company: ViiV Healthcare
  • Treatment for: HIV Infection

Selzentry (maraviroc) is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in patients 2 years of age and older.

Development History and FDA Approval Process for Selzentry

Nov  4, 2016Approval ViiV Healthcare Announces FDA Approval of Selzentry (maraviroc) for Use in Children and Adolescents Living With HIV
Aug  6, 2007Approval Pfizer's Selzentry (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA
Jun 21, 2007Pfizer Receives Approvable Letter From FDA For Maraviroc
Apr 25, 2007FDA Advisory Committee Recommends Accelerated Approval of Pfizer’s Maraviroc for Treatment-Experienced Patients
Feb 13, 2007Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.